Passa al contenuto
Merck

O7125

L-Ornithine L-aspartate salt

≥98% (TLC)

Sinonimo/i:

(S)-2,5-Diaminopentanoic acid L-aspartate salt

Slide 1 of 3
Autenticati per visualizzare i prezzi organizzativi e contrattuali.

Scegli un formato

Prezzi e disponibilità al momento non sono disponibili

Informazioni su questo articolo

Formula empirica (notazione di Hill):
C9H19N3O6
Numero CAS:
3230-94-2
Peso molecolare:
265.26
NACRES:
NA.26
PubChem Substance ID:
329818920
UNSPSC Code:
12352209
EC Number:
221-772-7
MDL number:
MFCD00058084

Documenti fondamentali

Visualizza tutta la documentazione

Vai a

Servizio Tecnico
Hai bisogno di aiuto? Il nostro team di scienziati qualificati è a tua disposizione.
Permettici di aiutarti

Nome del prodotto

L-Ornithine L-aspartate salt, powder

InChI key

IXUZXIMQZIMPSQ-ZBRNBAAYSA-N

InChI

1S/C5H12N2O2.C4H7NO4/c6-3-1-2-4(7)5(8)9;5-2(4(8)9)1-3(6)7/h4H,1-3,6-7H2,(H,8,9);2H,1,5H2,(H,6,7)(H,8,9)/t4-;2-/m00/s1

SMILES string

NCCC[C@H](N)C(O)=O.N[C@@H](CC(O)=O)C(O)=O

assay

≥98% (TLC)

form

powder

color

white to off-white

storage temp.

2-8°C

Quality Level

200

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Categorie correlate

Confronta articoli simili

Visualizza il confronto per intero

Mostra le differenze

1 of 4

Questo articolo
O2375O438675490
L-Ornithine L-aspartate salt powder

Sigma-Aldrich

O7125

L-Ornithine L-aspartate salt

L-Ornithine monohydrochloride ≥99%

Sigma-Aldrich

O2375

L-Ornithine monohydrochloride

L-Ornithine monohydrochloride BioXtra, ≥99%

Sigma-Aldrich

O4386

L-Ornithine monohydrochloride

DL-Ornithine monohydrochloride ≥99.0% (AT)

Sigma-Aldrich

75490

DL-Ornithine monohydrochloride

form

powder

form

powder

form

powder

form

powder

assay

≥98% (TLC)

assay

≥99%

assay

≥99%

assay

≥99.0% (AT)

storage temp.

2-8°C

storage temp.

-

storage temp.

-

storage temp.

-

color

white to off-white

color

white

color

white

color

-

Quality Level

200

Quality Level

200

Quality Level

200

Quality Level

100

Biochem/physiol Actions

L-Ornithine L-aspartate is a metabolite of arginine degradation by arginase. It has been shown to reduce blood ammonia concentrations by increasing ammoniadetoxification in the muscle and reducing the severity of hepatic encephalopathy in cirrhosis.

Other Notes

Product of arginine degradation by arginase

Classe di stoccaggio

11 - Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number
0000456907
0000456907
0000369173
0000369173
SLBW4848

Non trovi la versione di tuo interesse?

Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.

Cerca un COA

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Bin Zhang et al.
Bioresource technology, 284, 204-213 (2019-04-03)
l-ornithine, an important amino acid, is widely used in food and medicine industries. l-ornithine production mainly relies on microbial fermentation, which may not meet the industrial requirement owing to the poor fermentation ability of available strains. Herein, mscCG2 deletion, CgS9114_12202
Janus P Ong et al.
Clinical drug investigation, 31(4), 213-220 (2011-01-07)
Hepatic encephalopathy (HE) is a serious complication of cirrhosis. Clinical trials have consistently shown that L-ornithine-L-aspartate significantly improves HE symptoms. Health-related quality of life (HR-QOL) is impaired in HE patients and represents an important outcome measure for therapeutic intervention. The
Qian Jiang et al.
Journal of gastroenterology and hepatology, 24(1), 9-14 (2008-10-01)
Hepatic encephalopathy continues to be a major clinical problem and the current decade has not witnessed major therapeutic breakthroughs in this area. L-ornithine-l-aspartate (LOLA) is not frequently used as there are still some reservations about its benefits. The present study
Vibhu Vibhas Mittal et al.
European journal of gastroenterology & hepatology, 23(8), 725-732 (2011-06-08)
Minimal hepatic encephalopathy (MHE) impairs daily functioning and health-related quality of life (HRQoL). The modalities of treatment of MHE have not been adequately studied. To compare lactulose, probiotics, and L-ornithine L-aspartate (LOLA) in treatment of MHE and effect on HRQoL
Patrícia Coelho de Soárez et al.
Arquivos de gastroenterologia, 46(3), 241-247 (2009-11-18)
Experimental and clinical studies suggest that LOLA may have a favorable influence on hepatic encephalopathy due to the effect on the reduction of ammonia, and improvement of the symptoms and laboratory findings. To evaluate and to critically analyze the efficacy
Visualizza tutti i documenti correlati

Questions

Reviews

No rating value

Active Filters

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica